NCT03915964 (RA-BRIDGE) is a Phase 4 clinical trial of Baricitinib in Rheumatoid Arthritis, sponsored by Eli Lilly and Company.

Who is sponsoring NCT03915964?

NCT03915964 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT03915964?

Interventions in NCT03915964: Baricitinib, TNF Inhibitor.

What condition does NCT03915964 study?

NCT03915964 studies Rheumatoid Arthritis.

Is NCT03915964 still recruiting?

NCT03915964 is currently completed. Last updated 22 July 2025.

Last reviewed 2025-07-22 · How we verify

NCT03915964: RA-BRIDGE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

Completed Phase 4 Last updated 22 July 2025

What this trial tests

Phase 4 trial testing Baricitinib in Rheumatoid Arthritis in 2,663 participants. Completed in 28 May 2025.

Timeline

25 April 2019

Primary endpoint
28 May 2025

28 May 2025

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	2,663
Start date	25 April 2019
Primary completion	28 May 2025
Estimated completion	28 May 2025
Sites	261 locations across Italy, Poland, Denmark, Netherlands, Russia, Belgium, Lithuania, United States

Drugs / interventions tested

Baricitinib (baricitinib) — full drug profile →
TNF Inhibitor (tnf-inhibitor) — full drug profile →

Conditions studied

Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

18 and older, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
Bonelli M, Kerschbaumer A, Kastrati K, Ghoreschi K, et al · · 2024 · cited 95× · PMID 37923366 · DOI 10.1136/ard-2023-223850
Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases.
Salinas CA, Louder A, Polinski J, Zhang TC, et al · · 2023 · cited 77× · PMID 36371760 · DOI 10.1007/s40744-022-00505-1
Waiting for JAK inhibitor safety data.
Kragstrup TW, Glintborg B, Svensson AL, McMaster C, et al · · 2022 · cited 60× · PMID 35197363 · DOI 10.1136/rmdopen-2022-002236
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Bieber T, Feist E, Irvine AD, Harigai M, et al · · 2022 · cited 46× · PMID 36063279 · DOI 10.1007/s12325-022-02281-4
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience.
Taylor PC, Laedermann C, Alten R, Feist E, et al · · 2023 · cited 25× · PMID 37445562 · DOI 10.3390/jcm12134527
Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib.
Harrington R, Harkins P, Conway R. · · 2023 · cited 24× · PMID 37892827 · DOI 10.3390/jcm12206690
JAK-Inhibitors - A Story of Success and Adverse Events.
Wlassits R, Müller M, Fenzl KH, Lamprecht T, et al · · 2024 · cited 12× · PMID 38435420 · DOI 10.2147/oarrr.s436637
JAK Inhibitors for the Treatment of Axial Spondyloarthritis.
Klavdianou K, Papagoras C, Baraliakos X. · · 2023 · cited 11× · PMID 37654636 · DOI 10.31138/mjr.34.2.129

Verify or expand the search:

Other trials of Baricitinib

Trials testing the same drug.

NCT07543458 — Therapeutics for Moderate and Severe Dengue · Phase 3 · not yet recruiting
NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
NCT07268534 — Biologics in Folliculitis Decalvans : an Adaptative Trial Research · Phase 2 · not yet recruiting
NCT06923072 — Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement · Phase 2 · recruiting

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03915964 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 22 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03915964.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing